Stockscreener 앱 받기
130.50
0.64%
0.83
시장 영업 전:
130.17
-0.33
-0.25%
전일 마감가:
$129.67
열려 있는:
$129.5
하루 거래량:
5.01M
Relative Volume:
0.83
시가총액:
$162.02B
수익:
$29.79B
순이익/손실:
$9.22B
주가수익비율:
17.76
EPS:
7.3494
순현금흐름:
$10.23B
1주 성능:
-3.29%
1개월 성능:
-5.19%
6개월 성능:
+1.90%
1년 성능:
+22.93%
1일 변동 폭
$128.34
$132.34
1주일 범위
$128.34
$135.07
52주 변동 폭
$104.46
$157.29
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, NVS, AZN
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
130.50 | 160.99B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,021.41 | 881.12B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
230.00 | 551.06B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
213.76 | 369.98B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
150.44 | 284.59B | 54.66B | 13.58B | 16.05B | 7.0171 |
AZN
Astrazeneca Plc
|
184.64 | 285.23B | 60.48B | 10.40B | 8.05B | 3.3297 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 개시 | Jefferies | Buy |
| 2026-02-20 | 개시 | Barclays | Equal Weight |
| 2026-02-11 | 재확인 | Needham | Buy |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-08-19 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | 업그레이드 | Truist | Hold → Buy |
| 2025-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 재확인 | Oppenheimer | Outperform |
| 2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
| 2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 재확인 | Maxim Group | Buy |
| 2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Reduce |
| 2023-07-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 재개 | Piper Sandler | Overweight |
| 2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 재개 | BofA Securities | Neutral |
| 2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
| 2022-10-28 | 재확인 | Cowen | Outperform |
| 2022-10-28 | 재확인 | JP Morgan | Overweight |
| 2022-10-28 | 재확인 | Jefferies | Buy |
| 2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-10-28 | 업그레이드 | Truist | Hold → Buy |
| 2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
| 2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-02 | 재확인 | BofA Securities | Neutral |
| 2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-02-02 | 재확인 | Truist | Hold |
| 2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Argus | Hold → Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 재개 | Piper Sandler | Neutral |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
| 2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
| 2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-09-30 | 재개 | Jefferies | Buy |
| 2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-31 | 재확인 | Credit Suisse | Neutral |
| 2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 재확인 | Piper Sandler | Overweight |
| 2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
| 2020-07-31 | 재확인 | SunTrust | Hold |
| 2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
| 2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
| 2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
| 2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
Fideuram Intesa Sanpaolo Private Banking S.P.A. Takes $50.80 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Atle Fund Management AB Sells 27,373 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Yuhan expands API deals with Gilead, boosts South Korea productionCHOSUNBIZ - Chosunbiz
Yuhan Signs 210.2 Billion Won API Supply Deal with Gilead - Seoul Economic Daily
When Every Moment Matters: Kite’s CAR T-cell Therapy Helps Bring Hope to Patients - Gilead Sciences
Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases - GlobeNewswire Inc.
Daiwa Securities Group Issues Pessimistic Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
Resona Asset Management Co. Ltd. Lowers Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Profund Advisors LLC Buys 15,824 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (NASDAQ:GILD) Screens as a Top Dividend Stock with Strong Profitability and Health - ChartMill
Gilead Sciences Q1 2026 Earnings: Revenue Beat, Raised Guidance, and Key Analyst QuestionsNews and Statistics - IndexBox
Handelsbanken Fonder AB Sells 81,694 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
HighTower Advisors LLC Decreases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Latham & Watkins Advises on Gilead Sciences’ US$3 Billion Senior Unsecured Notes Offering - Legal Desire
MacroGenics stock (US5562221046): biotech shares jump after Vyloy FDA approval and takeover deal - AD HOC NEWS
Insider Sell Alert: Andrew Dickinson Sells Shares of Gilead Scie - GuruFocus
Gilead Sciences Inc (GILD) Stock Price, Trades & News - GuruFocus
Gilead Sciences (NASDAQ:GILD) Insider Sells $3,676,120.00 in Stock - MarketBeat
Gilead Sciences CFO Andrew Dickinson sells $396,810 in stock By Investing.com - Investing.com Australia
Gilead Sciences Insider Sold Shares Worth $3,676,199, According to a Recent SEC Filing - Moomoo
Gilead Sciences chief comm officer sells $3.68m of stock By Investing.com - Investing.com UK
Gilead Sciences chief comm officer sells $3.68m of stock - Investing.com
Gilead Sciences CFO Andrew Dickinson sells $396,810 in stock - Investing.com India
Gilead (GILD) CFO Andrew Dickinson sells 3,000 shares under 10b5-1 plan - Stock Titan
Gilead (GILD) executive sells 28,000 shares, exercises 25,000 options - Stock Titan
Gilead Sciences (NASDAQ: GILD) sells $3.0B of senior notes due 2028–2034 - Stock Titan
Cipla Flips Gilead’s ‘End Run’ Claim in Descovy Patent Fight - Bloomberg Law News
Gilead Sciences prices $3B multi-tranche senior notes offering - MSN
Gilead Sciences’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
WealthPlan Investment Management LLC Acquires 10,256 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
TD Private Client Wealth LLC Acquires 17,944 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
45,461 Shares in Gilead Sciences, Inc. $GILD Purchased by North Dakota State Investment Board - MarketBeat
Gilead Sciences, Inc. (GILD) Stock Analysis: Evaluating a 21.90% Upside Potential for Investors - DirectorsTalk Interviews
Erste Group Bank Predicts Gilead Sciences FY2026 Earnings - MarketBeat
Gilead Sciences Inc stock (US3755581036): dividend growth and HIV/oncology pipeline in focus - AD HOC NEWS
Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline - MarketBeat
Leuthold Group LLC Boosts Stake in Gilead Sciences, Inc. $GILD - MarketBeat
L & S Advisors Inc Invests $5.09 Million in Gilead Sciences, Inc. $GILD - MarketBeat
iA Global Asset Management Inc. Increases Position in Gilead Sciences, Inc. $GILD - MarketBeat
STF Management LP Sells 11,745 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
DNB Asset Management AS Increases Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Canada Post Corp Registered Pension Plan - MarketBeat
Abacus Wealth Partners LLC Buys Shares of 12,486 Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences to buy clinical-stage biotech Tubulis for up to $5 billion - MSN
Evaluating Gilead Sciences (GILD) Valuation After Q1 Beat Guidance Shift And New HIV Priority Review - Yahoo Finance
Gilead Sciences Inc stock (US3755581036): Insider share sale plans draw attention to valuation and p - AD HOC NEWS
Gilead Sciences, Inc. $GILD Shares Acquired by Commerzbank Aktiengesellschaft FI - MarketBeat
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch
Andrew Dickinson to sell 3,000 GILD shares, Form 144 (NASDAQ: GILD) - Stock Titan
Officer files Form 144 — GILD (NASDAQ: GILD) lists 25,000-share option sale - Stock Titan
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
길리어드 사이언스 주식 (GILD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Comm & Corp Aff Officer |
May 15 '26 |
Option Exercise |
66.64 |
25,000 |
1,666,000 |
153,779 |
| Mercier Johanna | Chief Comm & Corp Aff Officer |
May 15 '26 |
Sale |
131.29 |
28,000 |
3,676,199 |
125,779 |
1.30%
자본화:
|
볼륨(24시간):